Altered glycosylation in cancer: molecular functions and therapeutic potential
Xuemeng Xu,Qiu Peng,Xianjie Jiang,Shiming Tan,Wenjuan Yang,Yaqian Han,Linda Oyang,Jinguan Lin,Mengzhou Shen,Jiewen Wang,Haofan Li,Longzheng Xia,Mingjing Peng,Nayiyuan Wu,Yanyan Tang,Hui Wang,Qianjin Liao,Yujuan Zhou
DOI: https://doi.org/10.1002/cac2.12610
2024-09-21
Abstract:Glycosylation, a key mode of protein modification in living organisms, is critical in regulating various biological functions by influencing protein folding, transportation, and localization. Changes in glycosylation patterns are a significant feature of cancer, are associated with a range of pathological activities in cancer-related processes, and serve as critical biomarkers providing new targets for cancer diagnosis and treatment. Glycoproteins like human epidermal growth factor receptor 2 (HER2) for breast cancer, alpha-fetoprotein (AFP) for liver cancer, carcinoembryonic antigen (CEA) for colon cancer, and prostate-specific antigen (PSA) for prostate cancer are all tumor biomarkers approved for clinical use. Here, we introduce the diversity of glycosylation structures and newly discovered glycosylation substrate-glycosylated RNA (glycoRNA). This article focuses primarily on tumor metastasis, immune evasion, metabolic reprogramming, aberrant ferroptosis responses, and cellular senescence to illustrate the role of glycosylation in cancer. Additionally, we summarize the clinical applications of protein glycosylation in cancer diagnostics, treatment, and multidrug resistance. We envision a promising future for the clinical applications of protein glycosylation.